Finerenone in Diabetic-Kidney Disease: A Meta-Analysis of Renal & Cardiovascular Outcomes

Authors

  • Felicita Gracia Faculty of Medicine and Health Sciences, Universitas Bangka Belitung
  • Arya Marganda Simanjuntak Department of Internal Medicine, Faculty of Medicine, Universitas Riau
  • Samira Amanda Faculty of Medicine, Universitas Riau
  • Linda Ida Mustika Faculty of Medicine and Health Sciences, Universitas Bangka Belitung
  • Juwanto Department of Internal Medicine, Faculty of Medicine, Universitas Riau
  • Ligat Pribadi Sembiring Department of Internal Medicine, Faculty of Medicine, Universitas Riau
  • Jazil Karimi Department of Internal Medicine, Faculty of Medicine, Universitas Riau
  • Sari Harahap Department of Internal Medicine, Faculty of Medicine, Universitas Riau
  • Rosmaliana Department of Cardiovascular, Faculty of Medicine, Universitas Riau

DOI:

https://doi.org/10.22225/amj.6.2.2026.374-385

Keywords:

chronic kidney disease, cardiovascular, diabetes, finerenone, renal

Abstract

Abstract 

Diabetic kidney disease (DKD) is a major complication of type 2 diabetes, increasing cardiovascular risk. Existing treatments leave significant residual progression risk. Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, shows promise. This meta-analysis evaluates finerenone's effects on renal and cardiovascular outcomes in DKD. A Systematic Review and Meta-Analysis (PROSPERO CRD420251122382) followed PRISMA guidelines. PubMed, ScienceDirect, and Epistemonikos utilized and used keywords "Finerenone AND Diabetes AND Chronic Kidney Disease AND Outcomes." RCTs comparing finerenone to placebo in DKD, reporting renal or cardiovascular outcomes, were included. Data extraction covered study characteristics and outcomes. RevMan 5.4 analyzed data using a random-effects model. Risk of bias (RoB2) and certainty of evidence (GRADE-PRO) were assessed. Three RCTs (19,027 participants) were included for renal outcomes, and two RCTs (13,026 participants) for cardiovascular outcomes. Finerenone significantly reduced odds of sustained eGFR decline ?40% (OR 0.83, p=0.0003), ?57% (OR 0.86, p=0.0001), and the major composite kidney outcome (OR 0.76, p<0.0001). ESKD odds reduction (21%) was not statistically significant. For cardiovascular outcomes, finerenone significantly reduced hospitalization for heart failure (OR 0.78, p=0.0001). Trends towards reduced cardiovascular death (OR 0.88, p=0.09) were noted. Studies had low bias risk, and most outcomes showed moderate evidence certainty.Finerenone offers robust renoprotection and significantly reduces heart failure hospitalizations in DKD. finerenone as a key nonsteroidal mineralocorticoid receptor antagonist for comprehensive management, improving both renal and cardiovascular outcomes in this high-risk group.

Keywords: chronic kidney disease, cardiovascular, diabetes, finerenone, renal.

References

1. Mottl AK, Nicholas SB. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis. 2024 Mar;83(3):277–87. doi:10.1053/j.ajkd.2023.09.003

2. Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, Smith AE, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2023 Jul;402(10397):203–34. doi:10.1016/S0140-6736(23)01301-6

3. Uma A, Sivaraman S, Manoharan R, Periasamy P. Diabetic Kidney Disease in Type 2 Diabetes: A Comprehensive Review of Epidemiology, Pathophysiology, and Therapeutic Advances. J Pharm Bioallied Sci. 2025;17(2):33–5. doi:10.4103/jpbs.jpbs_1059_25 PubMed PMID: 40860001; PubMed Central PMCID: PMC12373389.

4. The Lancet. Diabetes: a defining disease of the 21st century. The Lancet. 2023 Jun;401(10394):2087. doi:10.1016/S0140-6736(23)01296-5

5. Genitsaridi I, Salpea P, Salim A, Sajjadi SF, Tomic D, James S, et al. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol. 2026 Feb;14(2):149–56. doi:10.1016/S2213-8587(25)00299-2

6. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 Jan 7;42(2):152–61.

7. Di Lullo L, Lavalle C, Scatena A, Mariani M, Ronco C, Bellasi A. Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist. J Clin Med. 2023 Jun 12;12(12):3992.

8. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219–29.

9. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252–63.

10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;n71.

11. Mc Causland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, et al. Finerenone and Kidney Outcomes in Patients With Heart Failure. J Am Coll Cardiol. 2025 Jan;85(2):159–68.

Downloads

Published

2026-07-29

Issue

Vol. 6 No. 2 (2026): June

Section

Articles

License

Copyright (c) 2026 Felicita Gracia, Arya Marganda Simanjuntak, Samira Amanda, Linda Ida Mustika, Juwanto, Ligat Pribadi Sembiring, Jazil Karimi, Sari Harahap, Rosmaliana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.